The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

21 May 2015 15:01

RNS Number : 9589N
MyCelx Technologies Corporation
21 May 2015
 



MyCelx Technologies Corporation

("MyCelx" or the "Company") (AIM: MYX)

 

21 May 2015

 

Grant of Share Option to Director

 

The Company announces that it has been notified on 20 May 2015 by Mark Clark, Chief Financial Officer and a director of the Company, that he was granted an option on 20 May 2015 under the MyCelx Omnibus Performance Incentive Plan ("Plan") over the Company's common shares of US$0.025 each ("Common Shares"). The grant to Mr. Clark was as follows:

 

Name of Director

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Mark Clark

20,000

US$2.15 *

81,667

0.44%

 

In addition, following this transaction, Mr. Clark continues to be interested in 47,553 Common Shares, representing 0.26 per cent of the present issued capital of the Company.

 

Grant of Share Option to Chief Business Development Officer

 

The Company further announces that it has been notified on 20 May 2015 by Connie Mixon, Chief Executive Officer and a director of the Company, that her husband Mark Mixon, Chief Business Development Officer, was granted an option on 20 May 2015 under the Plan over 76,000 Common Shares. The grant to Mr. Mixon was as follows:

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Mark Mixon

76,000

US$2.15 *

200,204

1.07%

 

In addition, following this transaction, Mr. Mixon continues to be interested in 10,000 Common Shares, representing 0.05 per cent of the present issued capital of the Company, which he holds as custodian for his son.

 

Following this transaction, Ms. Mixon is interested in an aggregate (including the interests of Mr. Mixon) of 991,210 Common Shares, representing 5.32 per cent of the present issued capital of the Company, and in options over an aggregate (including the interests of Mr. Mixon) of 363,221 Common Shares, representing 1.95 per cent of the present issued capital of the Company.

 

The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

 

The above grants formed part of wider grants of 319,000 options to a total of fifteen employees across the Company, on the same date, representing 1.71% of the current issued share capital.

 

The share options granted on 20 May 2015 will vest as to one third on each of the first, second and third anniversaries of the date of grant, and must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.

 

*Based on the mid-market closing price of the Company's Common Shares at 19 May 2015, and the closing US/£ exchange rate at that date.

 

 

For further information please contact:

 

MyCelx Technologies Corporation

Connie Mixon, CEO

Mark Clark, CFO

Tel: +1 888 306 6843

 

Numis Securities Limited

Corporate Finance

John Prior

Paul Gillam

 

Corporate Broking

James Black

Ben Stoop

Tel: +44 20 7260 1000

 

Bell Pottinger

Nick Lambert

Henry Lerwill

Tel: +44 20 3772 2500

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEVETILFIE
Date   Source Headline
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update
22nd Feb 20247:00 amRNSSaudi Arabia Business Operation Sale
21st Nov 20237:00 amRNSContract Update
16th Nov 20237:00 amRNSTrading Update
26th Sep 20233:10 pmRNSResult of Annual Meeting
20th Sep 20237:00 amRNSHalf Year Results Statement
11th Jul 20237:00 amRNSContract Award
5th Jul 20233:28 pmRNSHolding(s) in Company
3rd Jul 20232:37 pmRNSContract Award & PFAS Update
21st Jun 20237:00 amRNSMailing of AR and Notice of 2023 Annual Meeting
18th May 20237:00 amRNSFinal Results for the Year Ending 31 December 2022
12th May 20237:00 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSuccessful leach testing of PFAS media
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
8th Mar 20237:00 amRNSPilot Testing Agreement for PFAS Remediation
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
24th Jan 20237:00 amRNSContract Secured for PFAS Remediation System
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
16th Mar 20224:09 pmRNSHolding(s) in Company
11th Mar 20221:10 pmRNSDealings by Directors
11th Mar 20227:00 amRNSProposed Placing and Subscription
11th Feb 20227:00 amRNSTrading Update
2nd Feb 202211:07 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSSuccessful Trial of PFAS Remediation System
10th Jan 20227:00 amRNSAward of Green Economy Mark
23rd Nov 20212:36 pmRNSHolding(s) in Company
11th Nov 202111:51 amRNSDealings by Directors
9th Nov 20214:42 pmRNSDirector/PDMR Shareholding
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.